Assessment of Intracerebral Hematoma

Intracerebral Hematoma Clinical Trial

Official title:

Assessment of Intracerebral Hematoma Using Transcranial Duplex _ Hospital Based Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05158660
• Other study ID #: intracerebral hematoma
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2022
• Est. completion date: January 2023

Study information

• Verified date: December 2021
• Source: Assiut University
• Contact: waleed Gafar
• Phone: 00201012110708
• Email: waleed.gafar1995[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will assess acute intracerebral hematoma expansion within the first 48 hours from the onset using transcranial duplex sonography in patients who have acute intracerebral hematoma , and will also assess the correlation between the transcranial duplex sonography measurements and the clinical outcome of these patients .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: January 2023
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. first ever non traumatic supratentorial primary intracerebral haemorrhage on non contrast CT brain

2. admitted within 24 hours of symptom onset

Exclusion Criteria:

1. blood diseases, decompansated hepatic or renal impairment, or encephalopathy caused by electrolyte disturbance

2. on anticoagulant treatment

3. if devolped major complications during hospitalization ( e.g sever chest infection, hypoxia, or deep venous thrombosis )

4. comorbid neurological or psychiatric disorders

Related Conditions & MeSH terms

• Cerebral Hemorrhage
• Hematoma
• Intracerebral Hematoma

Intervention

Device:
• transcranial duplex sonography
it is an imaging device that will measure the intracerebral hematoma expansion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change from baseline in volume of intracerebral hematoma		at baseline, then 24 hour after the baseline, and finally 48 hours after the baseline